Drug Profile
Research programme: peptide therapeutics - Eli Lilly and Company/Zealand Pharma
Latest Information Update: 01 Jul 2015
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Zealand Pharma
- Class Peptide hormones
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 31 Aug 2013 Early research in Obesity in Denmark (unspecified route)
- 31 Aug 2013 Early research in Obesity in USA (unspecified route)
- 31 Aug 2013 Early research in Type-2 diabetes mellitus in Denmark (Parenteral)